Learn about the game-changing EMBER-3 trial. Dive into the results of Imlunestrant, a groundbreaking SERD for ER+, HER2- Advanced Breast Cancer.
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.
Empowering Oncology Professionals with Knowledge, Insights, and Innovation. Medicus Networks, Inc. 45121 Morgan Heights Rd, Temecula, CA 92592 All Rights
An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in…
Childhood cancer survivors in Europe exhibited higher risk for suicidal ideation than the general population, according to results of a systematic review and meta-analysis.This finding…
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction…
Journal of Neuro-Oncology – The resolution of peritumoral brain edema (PTBE) following surgery for intracranial meningioma (IM) is poorly understood. We hypothesized that PTBE represents…
ASTRO’s weekly member newsletter for the week of March 17: ROCR Act reintroduced, Don’t miss 2025 Refresher, Leadership Pathway Program Awardees
Resources for investigators to find and make publicly available genomic summary results (GSR) data from cancer research studies.
NCI researchers debuted a new deep learning model that could help you decipher the cancer tumor’s microenvironment. The model holds a lot of promise for…
